An applicator for an analyte monitoring device may include an actuatable housing having a body defining a cavity therein and having a distal opening and a side opening. A cuff and a shuttle are received within the cavity and are separately translatable relative to the housing body. A base may removable engage the housing body at the distal opening. The housing body, the cuff, the shuttle, and/or the base may be engaged with one another with one or more releasable coupling features. The base may be removed from an engagement with the housing body, causing the cuff and the shuttle to be aligned and positioned in a configuration in which the analyte monitoring device, held by the shuttle, is ready for insertion into the skin.

A fluid infusion system includes a housing configured to be adhesively coupled to an anatomy of the user. The housing comprises a communication device configured to wirelessly communicate a physiological characteristic to a communication component of a fluid infusion device. The fluid infusion system includes a fluid flow path from the fluid infusion device into the anatomy of the user, and the fluid flow path is configured to extend from the housing for insertion into the anatomy of the user.

Disclosed are devices for delivering a rheumatoid arthritis drug across a dermal barrier. The devices include microneedles for penetrating the stratum corneum and also include structures fabricated on a surface of the microneedles to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. The pattern of structures on the surface of the microneedles may include nano-sized structures.

Provided is a device for transdermal delivery of drugs. The device includes a separable substrate and is loaded with dual drugs based on an interpenetrating polymer network hydrogel. Also provided are methods of making and using the transdermal delivery device.

A hybrid microneedle array and a method of fabricating the array is used for delivery of drugs, vaccines, and other therapeutic agents into tissues, including skin, heart, inner ear, and other tissues. The microneedle array can facilitate precise and reproducible intradermal delivery. Each microneedle has a dissolvable tip with a hollow body permitting the delivery of a variety of therapeutic agents into the skin. A fabrication process utilizes a two part mold to separately mold a dissolvable tip and a solid body portion of each microneedle in the array.

An adhesive composite dressing useful for applying an active ingredient to a treated skin site, as well as methods of manufacture and use of such dressings. In one embodiment, an adhesive composite dressing comprising an anchor member, a target member, and a folding member, where the anchor member comprises a first skin-contact adhesive, the target member comprises an opening adapted to enable skin treatment, the folding member comprises a drug reservoir, and where the folding member is attached to the anchor portion through a hinge defined by a line of attachment that is not contiguous with an edge of the anchor member.

A closed-loop wearable device or platform integrates sensors, actuators, and microcontroller on board. The device is applied directly to the skin using stretchable epidermal electronics. It can sense a variety of signals from the human body, thus collecting medically relevant information, and can activate delivery of a therapeutic upon detection of an abnormal condition. The therapeutic can be delivered at a personalized dosage and/or with a unique combination of drugs or other agents based on the individual's metabolism as tracked by various sensor modules integrated with the medical device.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

A strap for a microneedle applicator according to the present disclosure, which is coupled to an applicator main body part of the microneedle applicator in the form of a wearable device to allow the microneedle applicator to be worn on the body, includes a strap part having a structure that is inflatable when air is injected thereinto, a main body connecting part installed at both ends of the strap part, a housing installed at one side of an outer surface of the strap part, a pump installed inside the housing and configured to supply air to be injected into the strap part, a valve installed inside the housing, connected to a communication path along which air is injected into the strap part, and configured to operate to inject air into the strap part or discharge air from inside the strap part to the outside, and a controller configured to control the pump and the valve.

Disclosed is a drug compliance management system including a microneedle applicator configured to infuse a drug by means of a microneedle in the form of a wearable device, a patient terminal configured to process drug compliance information including drug infusion information received from the microneedle applicator and medication information separately input by a patient after administration, a server configured to transmit the drug compliance information received from the patient terminal, and an expert terminal configured to display drug compliance information collected from a plurality of patient terminals.